S82. Proffered paper: In-vivo testing of PSMA-targeted T-cell immunotherapy for prostate cancer

Bone is the most common site for metastasis in human prostate cancer patients. Skeletal metastases are a significant cause of morbidity and mortality and overall greatly affect the quality of life of prostate cancer patients. Despite advances in our understanding of the biology of primary prostate tumours, our knowledge of how and why secondary tumours derived from prostate cancer cells preferentially localise in bone remains limited. Examining the impact of these facets of bone metastasis in vivo remains a significant challenge, as animal models that closely mimic the natural history and malignant progression of clinical prostate cancer are not available.